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Background and purpose: The aim of this study was to determine whether
early and late death are associated with different baseline factors in intracere-
bral haemorrhage (ICH) survivors.
Methods: This was a secondary analysis of the multicentre prospective obser-
vational CROMIS-2 ICH study. Death was defined as ‘early’ if occurring
within 6 months of study entry and ‘late’ if occurring after this time point.
Results: In our cohort (n = 1094), there were 306 deaths (per 100 patient-
years: absolute event rate, 11.7; 95% confidence intervals, 10.5–13.1); 156 were
‘early’ and 150 ‘late’. In multivariable analyses, early death was independently
associated with age [per year increase; hazard ratio (HR), 1.05, P = 0.003],
history of hypertension (HR, 1.89, P = 0.038), pre-event modified Rankin
scale score (per point increase; HR, 1.41, P < 0.0001), admission National
Institutes of Health Stroke Scale score (per point increase; HR, 1.11,
P < 0.0001) and haemorrhage volume >60 mL (HR, 4.08, P < 0.0001).
Late death showed independent associations with age (per year increase; HR,
1.04, P = 0.003), pre-event modified Rankin scale score (per point increase;
HR, 1.42, P = 0.001), prior anticoagulant use (HR, 2.13, P = 0.028) and the
presence of intraventricular extension (HR, 1.73, P = 0.033) in multivariable
analyses. In further analyses where time was treated as continuous (rather
than dichotomized), the HR of previous cerebral ischaemic events increased
with time, whereas HRs for Glasgow Coma Scale score, National Institutes of
Health Stroke Scale score and ICH volume decreased over time.
Conclusions: We provide new evidence that not all baseline factors associated
with early mortality after ICH are associated with mortality after 6 months
and that the effects of baseline variables change over time. Our findings could
help design better prognostic scores for later death after ICH.
Introduction
Most research on outcomes following intracerebral
haemorrhage (ICH) has focussed on short-term
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mortality (within 6 months), reflecting the high rates
of early death associated with this stroke subtype
[1,2]. Many factors associated with early mortality
relate to ICH severity and this is reflected in prognos-
tic scores that aim to predict outcome in the short
term [3–11]. Policies of active acute management,
including blood pressure lowering, prompt reversal of
anticoagulation and neurosurgical referral, aim to
improve prognosis in patients with ICH [12]. A
better understanding of the factors that influence ‘late’
death following ICH might identify potentially modifi-
able risk factors that could improve long-term out-
comes [1].
Our aim was to evaluate whether early and late
death are associated with different baseline factors in
ICH survivors using data from the prospective multi-
centre CROMIS-2 ICH study. We hypothesized that
factors relating to the severity of the acute ICH would
not be associated with death at later (beyond
6 months) time points.
Methods
Data availability statement
Analyses for the CROMIS-2 study are ongoing; once
all of these analyses are completed, the CROMIS-2
Steering Committee will consider applications from
other researchers for access to anonymized source data.
Participants
We included adults from the CROMIS-2 (Clinical
Relevance of Microbleeds in Stroke) ICH study; full
details of the study protocol have been published pre-
viously [13]. Further details are provided in the Sup-
porting Information. The study was approved by the
National Research Ethics Service (IRAS reference 10/
H0716/61). Informed written consent was obtained for
all participants.
Outcomes
The outcome of interest for this project was time to
death. Mortality notifications were received from
NHS Digital (previously the Health and Social Care
Information Centre) as detailed in the previously pub-
lished study protocol [13]. NHS Digital is a national
centralized body that collects data on health and
social care in the UK; mortality data are derived from
‘hospital episode statistics’ (records of all NHS patient
admissions) and information on registered deaths
from the Office of National Statistics (death registra-
tion is a legal requirement in the UK).
Patients were censored at either 3 years following
the ICH that resulted in study entry or at last avail-
able follow-up for vital status (the time of the study’s
last notification of deaths from NHS Digital, i.e. 31
October 2017), depending on which was earlier.
Imaging
Brain computed tomography imaging was acquired
acutely at the time of the index event as part of the
patient’s routine clinical care. Further details are pro-
vided in the Supporting Information.
Statistics
Statistical analysis was performed using Stata (version
15.1, StataCorp LLC, College Station, TX, USA). We
dichotomized time following ICH into ‘early’ (before
6 months) and ‘late’ (after 6 months) periods. We
used univariable Cox regression to calculate hazard
ratios (HRs) for all baseline variables collected to
review for associations during these two time periods.
Variables where the 95% confidence intervals (CI) did
not cross 1 were considered as statistically significant.
To explore this further, the effect of each baseline
variable was then allowed to vary linearly with time;
further details are provided in the Supporting Infor-
mation.
Results
All 1094 patients recruited to CROMIS-2 ICH were
included (Table 1). Follow-up was for a total of
2613.48 patient-years (median 3.00 years; interquartile
range, 2.31–3.00 years). There were 306 deaths (abso-
lute event rate, 11.7 per 100 patient-years; 95% CI,
10.5–13.1 per 100 patient-years; Fig. 1). The median
time between the index ICH event and study entry
was 4 days (interquartile range, 2–8 days).
Associations of ‘early’ versus ‘late’ death
Of the 306 deaths, 156 occurred within 6 months of
the index haemorrhage event (‘early’) and 150 deaths
occurred after 6 months and within 3 years of the
index ICH (‘late’). Baseline characteristics for both
groups are shown in Table 1.
Early death (Table 2) was associated with age,
hypertension, diabetes mellitus, atrial fibrillation, a
history of previous cerebral ischaemic events, pre-
event modified Rankin scale (mRS) score, anticoagu-
lant use prior to ICH, Glasgow Coma Scale (GCS)
and National Institutes of Health Stroke Scale
(NIHSS) scores at study entry. Imaging features at
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study entry that were significantly associated with
early death were Van Swieten score, ICH volume and
the presence of intraventricular extension. In a multi-
variable model including these variables, age at study
entry (per year increase; HR, 1.05; 95% CI, 1.02–1.08,
P = 0.003), history of hypertension (HR, 1.89; 95%
CI, 1.04–3.46, P = 0.038), pre-event mRS score (per
point increase; HR, 1.41; 95% CI, 1.17–1.70,
P < 0.0001), admission NIHSS score (per point
increase; HR, 1.11; 95% CI, 1.06–1.15, P < 0.0001)
and ICH volume >60 mL (HR, 4.08; 95% CI, 1.85–
8.96, P < 0.0001) remained associated with early
death.
When considering death later than 6 months
(Table 2), age, atrial fibrillation, smoking, pre-event
cognitive impairment, previous cerebral ischaemic
event, pre-event mRS score, anticoagulant use prior
to index ICH, increasing van Swieten score and the
presence of intraventricular extension showed signifi-
cant associations. In a multivariable model including
all variables with a significant association with late
death, only age at study entry (per year increase; HR,
1.04; 95% CI, 1.02–1.08, P = 0.003), pre-event mRS
score (per point increase; HR, 1.42; 95% CI, 1.16–
1.73, P = 0.001), anticoagulant use prior to ICH (HR,
2.13; 95% CI, 1.08–4.17, P = 0.028) and the presence
of intraventricular extension (HR, 1.73; 95% CI,
1.05–2.85, P = 0.033) remained associated with late
death.
We then investigated which baseline characteristics
showed a significant change in HR between the early
and late periods (Table 2). We found that HRs for
the presence of APOE e2, GCS score, NIHSS score
and ICH volume >60 mL showed evidence of signifi-
cant change between the early and late periods
(Table 2).
Table 1 Baseline characteristics
All Alive Early death (<6 months) Late death (≥6 months)
n 1094 788 (72.0%) 156 (14.3%) 150 (13.7%)
Age (years) 73.3  12.5 70.3  12.4 81.1  9.4 80.7  8.5
Sex, male 628 (57.4%) 468 (59.4%) 78 (50.0%) 82 (54.7%)
Hypertension 718 (66.7%) 505 (65.3%) 114 (73.6%) 99 (66.9%)
Hypercholesterolaemia 467 (44.0%) 322 (42.0%) 71 (47.7%) 74 (50.3%)
Diabetes mellitus 202 (18.6%) 132 (16.9%) 38 (24.4%) 32 (21.6%)
Atrial fibrillation 375 (37.4%) 215 (30.1%) 81 (56.3%) 79 (55.2%)
Smoking (at time of ICH) 114 (10.8%) 94 (12.4%) 12 (8.0%) 8 (5.6%)
Pre-existing cognitive impairment 251 (39.8%) 150 (34.3%) 54 (50.5%) 47 (54.7%)
Previous cerebral ischaemic event 241 (22.9%) 149 (19.5%) 44 (30.1%) 48 (33.8%)
Previous ICH 46 (4.3%) 28 (3.6%) 10 (6.7%) 8 (5.6%)
Pre-event mRS score 0 (0–1) 0 (0–1) 1 (0–3) 1 (0–2)
APOE e2, presence 189 (20.7%) 138 (20.8%) 31 (26.5%) 20 (15.3%)
APOE e4, presence 256 (28.1%) 196 (29.5%) 24 (20.5%) 36 (27.5%)
Medications
Antiplatelet use prior to ICH 267 (24.6%) 193 (24.7%) 38 (24.5%) 36 (24.2%)
Anticoagulant use prior to ICH 436 (40.1%) 261 (33.4%) 86 (55.5%) 89 (59.3%)
Antiplatelet use at discharge 65 (6.4%) 46 (6.2%) 8 (6.2%) 11 (7.8%)
Anticoagulant use at discharge 113 (10.7%) 78 (10.2%) 14 (9.5%) 21 (14.5%)
Clinical features at study entry
GCS score 15 (14–15) 15 (14–15) 14 (11–15) 15 (14–15)
NIHSS score 7 (3–13) 6 (3–11) 14 (7–19) 6 (3–12)
Imaging features at study entry
Lacunes, presence 98 (9.0%) 69 (8.8%) 15 (9.6%) 14 (9.3%)
Van Swieten score (WMC) 0 (0–2) 0 (0–2) 1 (0–3) 2 (0–3)
ICH location
Infratentorial 99 (9.1) 69 (8.8) 12 (7.7) 18 (12.0)
Deep 546 (50.0) 398 (50.6) 69 (44.2) 79 (52.7)
Lobar 447 (40.9) 319 (40.6) 75 (48.1) 53 (35.3)
ICH volume
<30 mL 886 (85.9) 655 (89.0) 106 (70.7) 125 (85.6)
30–60 mL 99 (9.6) 60 (8.2) 24 (16.0) 15 (10.3)
>60 mL 47 (4.6) 21 (2.9) 20 (13.3) 6 (4.1)
Intraventricular extension 301 (27.7) 183 (23.4) 68 (43.6) 50 (33.6)
Percentage values were calculated using the total number of patients for whom data were available as the denominator. Data are given as
mean  SD, n (%) and median (interquartile range). GCS, Glasgow Coma Scale; ICH, intracerebral haemorrhage; IQR, interquartile range;
mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; WMC, white matter changes.
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Further exploratory analysis of time-varying effects
We then performed exploratory analyses where time
was considered as a continuous measure (Table S1).
In these analyses, variables that showed significant
time-varying effects were history of a previous cerebral
ischaemic event (P = 0.0214), admission GCS score
(P = 0.0108), NIHSS score (P < 0.00001) and ICH
volume (P = 0.0439). The HRs of previous cerebral
ischaemic events increased with time, whereas those
for NIHSS score and ICH volume decreased with
time. The protective (negative association) of GCS
score also decreased with time.
Discussion
We provide new evidence that not all baseline factors
associated with early mortality after ICH are associ-
ated with mortality after 6 months. In analyses where
the time-varying effects of baseline variables were
allowed to vary continuously with time, we found that
the influence of measures of acute ICH severity
decreased over time, whereas those associated with
established cerebrovascular disease (previous cerebral
ischaemic events) increased over time. These results
support the argument that definitions of ‘early’ or
‘late’ death are necessarily arbitrary, as the impact of
some characteristics present at study entry vary con-
tinuously with time.
In our study, the factors that we found to be inde-
pendently associated with early death are in keeping
with other studies and reflected in pre-existing
prognostic scores that include these and other vari-
ables [4-11]. Differences between our results for associ-
ations with late death and those previously reported
[14,15] are likely to reflect our method of considering
early and late death independently; when considering
all death events together, we observed effects that
were similar to those previously reported. Addition-
ally, we observed that four variables (APOE e2, GCS
score, NIHSS score and ICH volume >60 mL) showed
significant differences in the magnitude of their effect
before and after 6 months (although the HRs for
APOE e2 were not statistically significant in them-
selves). This result confirms that, whereas GCS score,
NIHSS score and ICH volume are important predic-
tors of early mortality, their effect changes signifi-
cantly between the early and late periods, and thus
they are less useful for predicting mortality in the
longer term, as we hypothesized. Our analyses of lin-
ear time-varying effects on long-term mortality follow-
ing ICH are novel and demonstrate the potentially
complex interactions that can occur over time. These
analyses highlight the difficulties in defining what is
‘early’ death or a ‘short-term’ outcome; further work
that considers time-varying effects on mortality across
longer time scales is needed to guide this.
Our finding of an association between intraventricu-
lar extension and late death seems counterintuitive,
but illustrates the importance of our work and the
complicated manner in which baseline variables might
interact over time. Given that our cohort included
patients with milder strokes, we hypothesize that the
effect of intraventricular extension on early death was
Figure 1 Unadjusted cumulative mortality curve. [Colour figure can be viewed at wileyonlinelibrary.com]
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lost in the adjusted analyses because of larger magni-
tude effects associated with other factors associated
with ICH severity (NIHSS score and ICH volume).
We speculate that, when considering late death, the
effects of acute factors such as NIHSS score and ICH
volume were of smaller magnitude, and thus the
impact of intraventricular extension as a measure of
stroke severity became more apparent. We did
observe, in unadjusted analyses, that intraventricular
extension was associated with both early and late
death, but the magnitude of the association was smal-
ler for late death (Table 2).
Our study has a number of strengths, including
the number of patients, its multicentre design (which
increases generalizability), robust ascertainment of
follow-up events and the detailed clinical and radio-
logical data available for each participant. However,
there are limitations of our work. Our cohort is
comprised of survivors with mild strokes, as reflected
by the median NIHSS and GCS scores, low ICH
volumes and low early death rates. This cohort is
therefore unlikely to be representative of all patients
with ICH, particularly those with more severe haem-
orrhages. We were unable to adjust for acute compli-
cations of ICH or details relating to immediate care,
either active or care-limiting (i.e. do not resuscitate
orders or palliative pathways), all of which would
impact mortality. Additionally, we were unable to
comment on cause of death in our patients. Finally,
although we considered the time-varying effects of
variables recorded at study entry, the status of these
may have changed after this time point (e.g. antipla-
telet or anticoagulant use) and this could have influ-
enced our results.
Table 2 Univariable Cox regression analysis for early (before 6 months) and late (after 6 months) periods following intracerebral haemorrhage
(ICH)
‘Early’ ‘Late’ Time-varying coefficient P-value
Age (per year increase) 1.08 (1.06–1.10) 1.09 (1.07–1.11) 0.360
Sex, male 0.73 (0.53–1.00) 0.85 (0.62–1.18) 0.500
Hypertension 1.43 (1.00–2.04) 1.08 (0.77–1.52) 0.270
Hypercholesterolaemia 1.18 (0.86–1.63) 1.34 (0.97–1.85) 0.585
Diabetes mellitus 1.44 (1.00–2.07) 1.31 (0.89–1.94) 0.729
Atrial fibrillation 2.31 (1.66–3.21) 2.67 (1.92–3.71) 0.548
Smoking, current 0.70 (0.39–1.27) 0.45 (0.22–0.91) 0.337
Pre-existing cognitive impairment 1.32 (0.75–2.34) 2.13 (1.39–3.25) 0.336
Previous cerebral ischaemic event 1.50 (1.05–2.13) 1.90 (1.34–2.69) 0.345
Previous ICH 1.65 (0.87–3.14) 1.49 (0.73–3.04) 0.833
Pre-event mRS score (per point increase) 1.56 (1.40–1.74) 1.50 (1.33–1.69) 0.610
APOE e2, presence 1.40 (0.93–2.11) 0.70 (0.44–1.13) 0.032
APOE e4, presence 0.65 (0.42–1.02) 0.90 (0.61–1.32) 0.280
Medications
Antiplatelet use prior to ICH 0.98 (0.68–1.42) 0.96 (0.66–1.40) 0.936
Anticoagulant use prior to ICH 1.97 (1.44–2.71) 2.73 (1.97–3.78) 0.164
Antiplatelet use at discharge 0.95 (0.46–1.93) 1.23 (0.67–2.28) 0.582
Anticoagulant use at discharge 0.85 (0.49–1.48) 1.48 (0.93–2.35) 0.134
Clinical features at study entry
GCS score (per point increase) 0.80 (0.76–0.84) 0.93 (0.86–1.00) 0.001
NIHSS score (per point increase) 1.11 (1.08–1.14) 1.00 (0.97–1.04) <0.0001
Imaging features at study entry
Lacunes, presence 1.05 (0.62–1.79) 1.06 (0.61–1.84) 0.976
Van Swieten score (WMC, per point increase) 1.23 (1.11–1.36) 1.37 (1.23–1.51) 0.139
ICH location
Infratentorial Reference group
Deep 1.04 (0.57–1.93) 0.79 (0.47–1.32) 0.494
Lobar 1.42 (0.77–2.62) 0.67 (0.39–1.14) 0.067
ICH volume
<30 mL Reference group
30–60 mL 2.20 (1.41–3.42) 1.29 (0.75–2.20) 0.131
>60 mL 4.85 (3.01–7.83) 1.40 (0.62–3.18) 0.010
Intraventricular extension 2.20 (1.61–3.02) 1.55 (1.11–2.18) 0.141
Univariable hazard ratios (HRs) for each characteristic obtained by fitting Cox regression models with time-varying effects (before/after
6 months). Data are given as HR (95% confidence intervals). The time-varying coefficient P-value compares the difference between the early
and late HRs. GCS, Glasgow Coma Scale; mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale.
© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
ASSOCIATIONS OF EARLY AND LATE DEATH IN ICH SURVIVORS 1261
We provide new evidence that not all baseline fac-
tors associated with early mortality after ICH are
associated with mortality after 6 months. Our findings
could help design better prognostic scores for later
death after ICH.
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